An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Mifepristone (Primary)
- Indications Cushing syndrome
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
Most Recent Events
- 07 May 2015 New trial record